特此公告。 华润博雅生物制药集团股份有限公司董事会 2025年5月16日 证券代码：300294 证券简称：博雅生物 公告编号：2025-036 华润博雅生物制药集团股份有限公司 关于调整公司组织架构的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 华润博雅生物制药集团股份有限公司（以下简称公司）于2025年5月16日召 开了第八届董事会第十二次会议，审议通过了《关于调整公司组织架构的议案》。 为更好开展针对非党员的干部职工的监督执纪问责工作，不断提升纪检工作 规范化、法治化、正规化水平，公司成立华润博雅生物纪检部，与纪委办公室合 署办公，同时公司于2024年11月完成收购绿十字（中国）生物制品有限公司（以 下简称绿十字（中国）），新增成员企业绿十字（中国）。 本次组织架构调整是对公司内部管理机构的调整，不会对公司生产经营活动 产生重大影响。调整后的公司组织架构图详见附件。 附件： 公司组织架构 图 ...

证券代码：300294 证券简称：博雅生物 公告编号：2025-034 华润博雅生物制药集团股份有限公司 第八届董事会第十二次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 表决结果：9 票同意，0 票反对，0 票弃权。 经充分讨论，逐项表决通过了以下子议案： 1.1 关于聘任总裁的议案 经董事长提名，聘任副总裁任辉先生担任公司总裁并担任公司法定代表人。 华润博雅生物制药集团股份有限公司（以下简称公司）第八届董事会第十二 次会议于 2025 年 5 月 13 日以邮件及通讯方式通知，并于 2025 年 5 月 16 日在公 司会议室以现场加通讯表决的方式召开。会议应参加表决董事 9 人，实参加表决 董事 9 人。会议由董事长邱凯先生主持，公司全体监事出席会议，全体高级管理 人员列席会议。本次会议符合《中华人民共和国公司法》《中华人民共和国证券 法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》及《公司章程》等相关规定。经充 分讨论，审议通过了以下议案。 二、董事会 ...

二、总裁、副总裁、财务总监聘任情况 公司于 2025 年 5 月 16 日召开第八届董事会第十二次会议，审议通过《关于 聘任总裁、副总裁、财务总监的议案》。根据相关规定结合公司实际经营管理需 要，经公司董事长提名，聘任副总裁任辉先生担任公司总裁；经总裁提名，新增 聘任林青松先生担任公司副总裁，聘任董事潘宇轩先生担任公司财务总监。上述 人员任期自本次董事会审议通过之日起至本届董事会届满之日止。（高级管理人 员简历详见附件） 上述高级管理人员的任职资格已经公司董事会提名、薪酬与考核委员会审查 通过，董事会提名、薪酬与考核委员会出具了明确同意的审查意见。其中关于聘 任财务总监事项，公司董事会审计委员会出具了明确同意的审查意见。 三、法定代表人变更情况 证券代码：300294 证券简称：博雅生物 公告编号：2025-035 华润博雅生物制药集团股份有限公司 关于高级管理人员和法定代表人变更的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、总裁、财务总监辞任情况 华润博雅生物制药集团股份有限公司（以下简称公司）董事会于2025年5月 16日分别收到梁小明先生和梁化成 ...

Core Viewpoint - Hemophilia is a hereditary bleeding disorder primarily treated through factor replacement therapy, with significant advancements in drug development leading to increased demand and market growth in China [1][6][20]. Industry Definition and Categories - Hemophilia is characterized by a deficiency in clotting factors, leading to prolonged bleeding tendencies, and can be classified into Hemophilia A and B, with A being more prevalent [2][3]. Current Industry Status - The demand for hemophilia drugs is on the rise due to advancements in diagnosis and treatment, with a projected demand of 5.8236 million doses in 2024 and 7.3154 million doses in 2025, reflecting a growing market size from 5.361 billion yuan in 2024 to 5.856 billion yuan in 2025 [6][9]. Market Competition Landscape - Major domestic companies in the hemophilia drug market include Beijing Shenzhou Cell Engineering, Shandong Taibang Biological Products, Henan Hualan Biological Engineering, and Shanghai Raist Blood Products, among others [13][14]. Industry Development Trends - The hemophilia drug industry is expected to benefit from technological innovations and increased awareness, leading to a broader market outlook as more patients can afford treatment and government support for rare diseases grows [20].

关于控股股东增持公司股份计划实施完成的公告 公司控股股东华润医药控股有限公司保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 证券代码：300294 证券简称：博雅生物 公告编号：2025-033 华润博雅生物制药集团股份有限公司 特别提示： 1、华润博雅生物制药集团股份有限公司（以下简称公司或博雅生物）于 2024 年 12 月 18 日在巨潮资讯网上披露了《关于控股股东增持公司股份达到 1%暨后 续增持计划的公告》，公司控股股东华润医药控股有限公司（以下简称控股股东 或华润医药控股）自 2024 年 11 月 8 日起 6 个月内拟通过证券法规允许的方式增 持公司股份，总增持股份数量不低于总股本的 1%（即 504.24 万股），且不超过 总股本的 1.2%（即 605.09 万股）。本次增持不设定价格区间，将根据市场整体 变化趋势和公司股票交易价格的波动情况，择机实施增持计划。 2、自 2024 年 11 月 8 日-2025 年 5 月 7 日，华润医药控股通过深圳证券交易 所证券交易系统集中竞价交 ...

北京市天元律师事务所 关于华润博雅生物制药集团股份有限公司控股股东 增持股份的 专项法律意见 北京市天元律师事务所 北京市西城区金融大街 35 号 国际企业大厦 A 座 509 单元 邮编：100033 北京市天元律师事务所 关于华润博雅生物制药集团股份有限公司控股股东 增持股份的 北京市天元律师事务所（以下简称"本所"）接受华润医药控股有限公司（以 下简称"华润医药控股"或"增持人"）的委托，根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司收购管理办法》（以下简称"《收购管理办法》"）《深圳证券交易所上 市公司自律监管指引第2号——创业板上市公司规范运作》以及其他相关法律法 规的有关规定，就华润博雅生物制药集团股份有限公司（以下简称"博雅生物"、 "公司"）控股股东华润医药控股增持博雅生物股份的事宜（以下简称"本次增持"） 出具法律意见。为出具本法律意见，本所律师声明如下： 本所及经办律师依据《证券法》、《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见出具日以前已经发 生或者存在的事实，严 ...

华润博雅生物制药集团股份有限公司 证券代码：300294 证券简称：博雅生物 公告编号：2025-032 公司董事会对陈兵先生在任职期间为公司发展做出的努力和贡献表示衷心 感谢！ 关于公司高级管理人员辞职的公告 本公司及董事会全体成员保证公告内容真实，准确和完整，没有虚假记载， 误导性陈述或重大遗漏。 特此公告。 华润博雅生物制药集团股份有限公司董事会 2025 年 5 月 7 日 华润博雅生物制药集团股份有限公司（以下简称公司）董事会于2025年5月7 日收到公司高级管理人员陈兵先生递交的书面《辞职报告》，陈兵先生因个人原 因申请辞去公司副总裁职务。根据《中华人民共和国公司法》《公司章程》等相 关规定，陈兵先生的辞职报告自送达公司董事会之日起生效。陈兵先生辞职后将 不再担任公司任何职务，不会影响公司相关工作的正常开展。 截至本公告披露日，陈兵先生持有公司股份71,300股，占公司总股本的 0.01%，其不存在应履行而未履行的承诺事项。陈兵先生就任时确定的任期为2024 年03月21日至2027年03月20日，辞职后，其在就任时确定的任期内和任期届满后 六个月内，继续遵守《上市公司董事、监事和高级管理人员所持 ...

Investment Rating - The investment rating for the company is "Buy" [4] Core Views - The company has shown steady growth in plasma collection, with a total of 630.6 tons collected in 2024, representing a year-on-year increase of 10.4% [2] - The company has a diverse product line with 11 varieties and 31 specifications, including human immunoglobulin and coagulation factors [2] - The revenue from blood products in 2024 was 15.14 billion yuan, a slight increase of 0.86% year-on-year, despite a competitive market leading to price declines [2][3] - The company is expanding its research pipeline and has received regulatory approvals for products aimed at international markets, including a registration certificate for immunoglobulin in Pakistan [3] Summary by Sections Financial Performance - In 2024, the company achieved total revenue of 17.35 billion yuan, a decrease of 34.58%, while net profit attributable to shareholders was 3.97 billion yuan, an increase of 67.18% [1] - For Q1 2025, total revenue was 5.36 billion yuan, up 19.49%, but net profit decreased by 8.25% to 1.39 billion yuan [1] Product and Market Development - The company has 20 operational plasma collection stations and one under construction, totaling 21 stations [2] - The company is focusing on optimizing product structure and enhancing production processes to drive revenue growth in blood products [2] Profitability Metrics - The gross margin for the company in 2024 was 64.65%, an increase of 11.90 percentage points compared to the previous year, but it decreased to 53.80% in Q1 2025 [3] - The company’s projected net profits for 2025, 2026, and 2027 are 5.20 billion yuan, 5.98 billion yuan, and 6.54 billion yuan, respectively [9]

Investment Rating - The investment rating for the company is "Buy" with expectations of a relative price increase of over 15% in the next six months [4][15]. Core Insights - The company reported a total revenue of 1.735 billion yuan in 2024, a decrease of 34.58% year-on-year, while the net profit attributable to shareholders was 397 million yuan, an increase of 67.18% [1][2]. - In Q1 2025, the company achieved a total revenue of 536 million yuan, reflecting a year-on-year growth of 19.49%, but the net profit attributable to shareholders decreased by 8.25% to 139 million yuan [1][2]. - The company has a stable growth in plasma collection, with a total collection of 630.6 tons in 2024, representing a year-on-year increase of 10.4% [2]. - The company has 11 product varieties and 31 specifications, including imported recombinant factor VIII, and operates 20 plasma stations with one under construction [2]. - The revenue from blood products in 2024 was 1.514 billion yuan, a slight increase of 0.86% year-on-year, despite a competitive market leading to a decline in product gross margins [2][3]. Summary by Sections Financial Performance - The company’s revenue is projected to grow to 1.971 billion yuan in 2025, with a growth rate of 13.62%, and further to 2.242 billion yuan in 2026 [3][10]. - The net profit is expected to reach 519 million yuan in 2025, reflecting a growth rate of 30.86%, and 597 million yuan in 2026 [3][10]. - The earnings per share (EPS) are forecasted to be 1.03 yuan in 2025 and 1.18 yuan in 2026 [3][10]. Research and Development - The company is expanding its research pipeline with a focus on both long-term and short-term strategies, including the approval of drug registration certificates for certain products expected to launch in 2025 [3]. - The company has received drug registration approval for its immunoglobulin product in Pakistan, which is anticipated to enhance overseas revenue [3]. Market Position - The company is experiencing pressure on gross margins due to rising costs and increased competition in the blood products sector, with gross margins reported at 64.65% in 2024 [3][9]. - The company’s sales, management, and financial expense ratios were 33.47% in 2024, indicating an increase in operational costs [9].

Core Viewpoint - The blood products industry, once considered a "golden track," is facing significant challenges in Q1 2025, with major companies experiencing over 20% declines in net profits, contrasting sharply with their strong performance in 2024. This downturn is attributed to a combination of price wars, inventory buildup, and technological substitution [1]. Group 1: Financial Performance - TianTan Bio reported a revenue increase of 7.84% to 1.318 billion yuan, but its net profit plummeted by 22.9%. Operating cash flow fell by 65.75%, and accounts receivable surged by 1093%, indicating deteriorating sales collection efficiency [2]. - Boya Bio's revenue grew by 19.49%, yet its net profit decreased by 8.25%, with core products like human albumin seeing price declines of 2.65% to 12% [2]. - Pailin Bio experienced a revenue drop of 14% and a net profit decline of 26.95%, with operating expenses rising to 18.04%, indicating a failure in cost control [2]. - Shanghai Laishi's net profit growth rate fell from 23.25% to -25.20%, highlighting operational pressures despite expansion efforts [2]. Group 2: Industry Dynamics - The industry's sudden performance decline is driven by price wars, inventory accumulation, and technological substitution. In 2024, blood product inventory growth (36.02%) significantly outpaced cost growth (7.12%), forcing companies to lower prices to clear stock. The terminal price of human albumin has dropped to 350-380 yuan per bottle [3]. - Although not included in national procurement, regional alliance negotiations and competition from imported products create "invisible procurement pressure," with imported albumin's market share rising to 69% and over 70% in tertiary hospitals [3]. - Disruptive technologies are eroding the industry's competitive advantages, with plant-based recombinant albumin potentially reducing costs to below 10 yuan per gram, halving current blood-derived product prices. Additionally, recombinant coagulation factor VIII has captured a 30 billion yuan market share, further compressing the premium space for blood-derived products [3]. Group 3: Opportunities and Challenges - The reliance on imports and the threat from recombinant technologies make domestic production crucial for overcoming current challenges. Tariffs on imports from the U.S. could increase imported albumin prices by 10%-15%, highlighting the cost-effectiveness of domestic products, which currently hold a 31% market share that needs to rise above 50% [4]. - Leading companies are accelerating technological advancements, with TianTan Bio achieving a revenue of over 6 million yuan per ton of plasma and aiming for a 50% domestic production rate for coagulation factors. Shanghai Laishi is investing 4.2 billion yuan to acquire Nanyue Bio, increasing its plasma collection stations to over 50, with the top five companies controlling over 80% of plasma collection [4]. - However, the disruptive threat from recombinant technologies remains, with the clinical adaptation and market education for recombinant albumin expected to take 5-8 years, providing traditional companies with a valuable window for transformation [4]. Group 4: Conclusion - The blood products industry's challenges are not coincidental but rather a painful transition in market logic. As price wars and inventory pressures push companies towards efficiency competition, the race for survival in this trillion-yuan market will test not only the number of plasma collection stations but also product quality, cost control, and strategic foresight [5].